Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FT1T8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,424
Award facts
- Contract value 100% obligated
- $3,424.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $3,424.46 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for XOLAIR 300 mg/2 ml autoinjector vials. The delivery order was awarded on October 22, 2025, with an ultimate completion date of November 13, 2025, and does not include a set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
DMS Pharmaceutical Group holds a single-award IDC under the PPV-G GEN V program with a $499,999,999 ceiling value and completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The prime contractor position enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, biologics, and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide. The company's registration in the System for Award Management dates to July 18, 2001, and recent delivery orders demonstrate its established capability to fulfill specialized pharmaceutical requirements across multiple therapeutic categories for the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FT1T8?
SPE2DB26FT1T8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 22, 2025.
How much is contract SPE2DB26FT1T8 worth?
The government has obligated $3,424 on SPE2DB26FT1T8.
Is contract SPE2DB26FT1T8 an order under another contract?
Yes. SPE2DB26FT1T8 is a delivery order under SPE2DB20D9371, an indefinite delivery contract.
Was contract SPE2DB26FT1T8 competed?
The extent of competition for SPE2DB26FT1T8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award